The primary indication for administration of calcitriol or other vitamin D receptor activators (VDRA) in chronic kidney disease (CKD) is secondary hyperparathyroidism (SHPT). Prevention and treatment of SHPT appears important, as imbalances in mineral metabolism are associated with renal osteodystrophy, and higher parathyroid hormone (PTH) levels are associated with increased rates of mortality and morbidity in CKD patients. There is, however, a lack of controlled trial data that show lowering PTH with calcitriol/VDRA equates to improved clinical outcomes. Recent randomized controlled trials have concentrated on potential benefits of calcitriol/VDRA on cardiovascular outcomes and reduction of proteinuria and on possible differences between calcitriol and the various VDRA. Several systematic reviews and meta-analyses have also been published, evaluating the benefits and harms of calcitriol/VDRA. Concerns have been raised about the effectiveness of calcitriol/VDRA for suppression of SHPT in the CKD stages 3-5 population, as well as potential adverse outcomes such as hypercalcaemia and elevation in FGF23 levels, suggesting their routine use to treat SHPT in the pre-dialysis CKD population may not be favourable. Conversely, concerns still exist about the wide PTH range in advanced CKD, and that high values may negatively impact bone quality, result in the progression of parathyroid hyperplasia and decrease the effectiveness of treatments to reduce PTH. We discuss the current controversies relating to the challenges in the management of SHPT in patients with CKD stages 3-5 and the need for more evidence to determine the efficacy or harm of using calcitriol/VDRA in this population.
INTRODUCTION
Chronic kidney disease (CKD) results in a cascade of changes in mineral metabolism, which produce a rise in circulating parathyroid hormone (PTH) levels and the characteristic abnormalities of secondary hyperparathyroidism (SHPT). Management of elevated PTH levels in CKD has been a therapeutic focus for over 40 years. SHPT is associated with morbidity and mortality in patients with CKD stages 3-5D, and observational studies consistently report an increased relative risk (RR) of death in dialysis patients who have PTH values at the extremes for this population (less than twice, or greater than nine times, the upper normal limit of the assay). 1, 2 Once developed, severe SHPT may be resistant to medical/ pharmacological therapy, and marked parathyroid hyperplasia when associated with hypercalcaemia necessitates treatment with a parathyroidectomy. Treatment with 'active' vitamin D, either calcitriol or vitamin D receptor activators (VDRA), has been the cornerstone for the prevention and management of SHPT in patients with CKD. Observational data suggest a mortality benefit with the use of VDRA in dialysis populations, 3, 4 although this has been contested by other studies. 5 Furthermore, other studies suggest a benefit beyond the parathyroid-bone axis. 6, 7 However, there are concerns raised by recent trials about the effectiveness of calcitriol/VDRA in the CKD stage 3-4 population, with potential adverse outcomes such as hypercalcaemia and elevation in fibroblast growth factor 23 (FGF23) levels.
Vitamin D receptor activators, secondary hyperparathyroidism and chronic kidney disease
The importance of renal 1,25-dihydroxycholecalciferol (calcitriol) synthesis is well described, and alterations in vitamin D metabolism are a key feature of CKD mineral and bone disorder (CKD-MBD). 8 The progressive decrease in renal calcitriol synthesis seen in CKD is predominantly an active process mediated by the counter-regulatory effects of increasing FGF23 levels, 9 in addition to the passive effect of loss of renal parenchyma, and these decreased calcitriol levels and resulting hypocalcaemia are major stimuli to PTH secretion. The pathogenesis of SHPT in CKD is further complicated by disordered phosphate homeostasis and elevations in FGF23. The incidence and severity of SHPT increases with worsening renal function, resulting in parathyroid cell proliferation and hyperplasia and leading to abnormalities in bone mineralisation and turnover.
There has been difficulty in establishing an appropriate target range for serum PTH in patients with CKD for several reasons. These include cross-sectional studies showing that median PTH values increase, and the range widens with progressive CKD, methodological problems regarding the measurement of PTH, and increasing resistance of bone to the actions of PTH as kidney function deteriorates. 10 Additionally, the predictive value of PTH for underlying bone histology remains poor when intact PTH values are between approximately two and nine times the assay's normal upper range.
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Calcitriol or VDRA therapy has been the predominant treatment for SHPT in CKD, with a large body of clinical practice and experience. Administration of calcitriol or VDRA, such as paricalcitol, doxercalciferol and alfacalcidol, results in suppression of PTH levels. However, these therapies can also increase serum calcium, phosphate and FGF23 levels. Calcitriol/VDRA act through the vitamin D receptor (VDR) to inhibit PTH secretion. However, in addition to tissues involved in mineral homeostasis, the VDR has also been identified in many organs including vascular smooth muscle, endothelial cells and cardiac tissue. 12, 13 There has been increasing interest in the potential pleiotropic effects of vitamin D therapy, including effects on kidney disease per se (proteinuria, renal fibrosis and renal function) as well as cardiovascular morbidity and mortality.
Clinical guidelines and recent studies
The Kidney Disease Improving Global Outcomes (KDIGO) CKD-MBD guidelines were published in 2009, and Table 1 outlines aspects relating to management of SHPT from these guidelines. 14 The low level of evidence and, therefore, weak recommendations highlight the lack of randomized controlled trials (RCT) that define an optimal PTH level for patients with CKD stages 3-5. Data on clinical endpoints such as hospitalization, fracture or mortality are similarly lacking. A recent review of the KDIGO guidelines suggested a revision of the previous statement relating to targeting normal PTH levels in pre-dialysis CKD patients, with appreciation that modest increases in PTH most likely represent an appropriate adaptive response to declining kidney function; further, it was suggested that in CKD stages 3-5, only PTH levels that were 'persistently elevated' or 'progressively rising' should warrant further investigation and management. 15 Treatment of SHPT with calcitriol/VDRA has historically been supported by RCT of patients with CKD stages 3-5D, showing that these agents lower levels of serum PTH compared with placebo. [16] [17] [18] Two well-conducted RCT in patients with CKD stages 3-5 also evaluated bone histomorphometry reporting benefits with calcitriol/VDRA compared with placebo. 19, 20 These trials led to a recommendation in the 2009 guidelines to treat elevated PTH levels with calcitriol/VDRA early in CKD to prevent parathyroid hyperplasia and skeletal consequences. However, the two RCT involving bone biopsies were published over 20 years ago and may not be relevant to current practice, and although benefits were predominantly related to suppression of SHPT, adverse effects of hypercalcaemia were of concern. 3. In patients with CKD stages 3-5D, the measurement of serum PTH or bonespecific ALP can be used to evaluate bone disease, as markedly high or low values predict bone turnover (2B). Treatment 1. In patients with CKD stages 3-5 not on dialysis, the optimal PTH level is not known. a. Patients with PTH levels above the upper normal limit should be evaluated for other abnormalities of CKD-MBD (2C), and these should be corrected (not graded).# 2. In patients with CKD stage 3-5 not on dialysis, where serum PTH is rising and remains persistently elevated despite the correction of modifiable factors, treatment with calcitriol or VDRA should be used (2C).# 3. Initial drug selection for the treatment of elevated PTH should be based on serum calcium and phosphate levels and other aspects of CKD-MBD (not graded). 4. In patients with CKD stage 5D, PTH levels should be maintained in the range of two to nine times the upper normal limit of the assay (2C). 5. Calcitriol/VDRA (and calcimimetics) can be used to lower PTH in patients with CKD stage 5D where PTH is elevated or rising (2B). 6. Calcitriol/VDRA should be reduced or stopped if (i) PTH levels fall below two times the upper limit of normal in CKD stage 5D (2C), and/or (ii) patients develop hypercalcaemia (2D).
*Level of evidence in parentheses. #These guideline statements will likely be revised in the updated KDIGO Guidelines in 2017. Abbreviations: ALP, alkaline phosphatase; CKD, chronic kidney disease; KDIGO, Kidney Disease Improving Global Outcomes; MBD, mineral and bone disorder; PTH, parathyroid hormone; SHPT, secondary hyperparathyroidism; VDRA, vitamin D receptor activators.
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Recent RCT have been published since the 2009 KDIGO CKD-MBD guidelines, and two studies in particular have demonstrated increased incident hypercalcaemia when compared with earlier studies. 21, 22 The current draft CKD-MBD guidelines (http://www.kdigo.org/clinical_practice_guidelines/CKDMBD%20Update/KDIGO%20CKD-MBD%20Update_Public% 20Review_Final.pdf: last accessed 22 January 2017) now comment that the benefit to risk ratio may no longer be favourable, with the routine use of calcitriol/VDRA in CKD 3-5 no longer recommended, and instead, these agents should be reserved for severe and progressive SHPT. The two RCT discussed were the PRIMO and OPERA studies, which failed to show a beneficial effect of paricalcitol on cardiac structure and function in CKD patients. A significant reduction in PTH was observed in both studies, but with an increased risk of hypercalcaemia. The PRIMO trial evaluated the effect of paricalcitol on cardiac magnetic resonance imaging measures of the left ventricular mass index (LVMI) and diastolic function over 48 weeks in 227 participants with CKD stages 3 and 4 and moderate left ventricular hypertrophy (LVH). 21 Although treatment with paricalcitol promptly reduced PTH levels and maintained them within the normal range, neither the change in LVMI nor Doppler measures of diastolic dysfunction differed between treatment groups. However, episodes of hypercalcaemia were more frequent in the paricalcitol group (20.9%) compared with the placebo (0.9%) group. The OPERA study was a trial of the effect of 52 weeks of paricalcitol on magnetic resonance imaging measures of LVMI and echocardiograph measures of cardiac function in 60 participants with non-dialysis CKD stages 3-5 and LVH. 22 Paricalcitol was again associated with prompt reductions in PTH but was not associated with changes in LVMI or cardiac function. Hypercalcaemia occurred in 43.3% and 3.3% of participants randomized to paricalcitol and placebo, respectively. The primary differences in the OPERA and PRIMO studies were the smaller sample size in OPERA, and that LVMI of the OPERA subjects was at least 70% greater compared with those in PRIMO. Thus, OPERA provided important evidence in a cohort with more severe CKD, more severe SHPT and frank LVH that paricalcitol had no effect on reduction of LVMI over 12 months. In both studies, cardiovascular-related hospitalisations were lower in the treated groups, but these were secondary or post hoc analyses requiring further confirmation. In addition, there was no assessment of whether low dose treatments, avoidance of hypercalcaemia or the targeting of a higher range for PTH values might have long-term non-cardiac benefits.
One recent study was the first to directly compare cinacalcet and VDRA as monotherapies to lower PTH in the dialysis population. 23 This 12 month randomized, open-label study enrolled 312 participants on haemodialysis with PTH >45 pmol/L to either cinacalcet or VDRA and evaluated the percentage change in PTH level. The mean percentage change from baseline in PTH was À12.1% (À20.0% to À4.1%) in the cinacalcet arm and À7.0% (À14.9% to 0.8%) in the VDRA arm, a non-significant difference of À5.0% (À15.4% to 5.4%). There was also no difference in achievement of secondary efficacy endpoints between arms. Hypocalcaemia was more common in the cinacalcet arm, whereas hypercalcaemia and hyperphosphataemia occurred more often in the VDRA arm. There has not been any other recent literature to suggest a need to revise the 2009 KDIGO guidelines regarding the use of calcitriol/VDRA to treat SHPT in dialysis patients. However, more research is necessary to determine the appropriate setting for these agents in dialysis, including studies to determine at what degree of SHPT they are beneficial and address concerns about hypercalcaemia, hyperphosphataemia, vascular calcification and elevations in serum FGF23.
Potential benefits of calcitriol/vitamin D receptor activators in chronic kidney disease

Laboratory endpoints
The effects of calcitriol/VDRA therapy on biochemical endpoints in CKD are well documented, especially in regard to reduction of PTH levels. Numerous previous studies have reported significant reductions of PTH levels with calcitriol or VDRA in CKD stages 3 and 4 when compared with placebo, 16, 19, 24 and recent RCT have also demonstrated vitamin D treatment effectively lowers PTH levels in CKD stages 3-5. 21, 22 Therefore, there is a well-established cause and effect between calcitriol/VDRA and suppression of SHPT, although the effect of this on bone health remains less clear. Their prescription for PTH suppression may also increase in Australia with the withdrawal of reimbursement for cinacalcet as a readily available therapy for the treatment of SHPT. Many of the uncertainties associated with the use of calcitriol/ VDRA mirror the ambiguity regarding the optimal PTH target and the broader issues of using PTH as a marker of CKD-MBD. Additionally, calcitriol/VDRA may have effects beyond the bone-parathyroid axis, with increasing evidence for a benefit of these agents on reduction of proteinuria in patients with CKD stages 3-5 (and, extrapolating this, the potential to slow progression of renal disease, although this has not been reported to date). Supporting evidence is nicely summarized in the systematic review by de Borst MH et al.
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Cardiovascular protection
There may also potentially be cardiovascular benefits of calcitriol/VDRA, although not directly shown in PRIMO and OPERA, with a recent meta-analysis reporting reduction in cardiovascular events with VDRA despite no change in cardiac structure/function. 7 This meta-analysis involving 731 patients from seven clinical trials of calcitriol/VDRA (five paricalcitol, two calcitriol) was compared with placebo or no treatment and reported a reduced incidence of cardiovascular events with calcitriol/VDRA treatment (RR 0.27 (95% 
Reduction in proteinuria
Over the last 10 years, there has been an increasing appreciation of potential non-mineral effects of vitamin D therapy, including effects on blood pressure and proteinuria. Studies in animal models of CKD have suggested that proteinuria, renal fibrosis and loss of renal function may be reduced by treatment with calcitriol/VDRA, not only as monotherapy but also as adjunctive therapy to blockade of the renin-angiotensinaldosterone system (RAAS). 25 There have been several recent RCT assessing the role of calcitriol or VDRA on reduction of proteinuria in CKD patients. The largest of these, the VITAL study, demonstrated that 2 μg paricalcitol per day achieved the secondary endpoint with an effect of decreasing albuminuria in 281 patients with diabetic nephropathy and RAAS blockade over 24 weeks. 26 A recent meta-analysis addressed the effect of calcitriol/VDRA and proteinuria in CKD and included six studies (four with paricalcitol, two with calcitriol) involving 688 patients, with the vast majority on RAAS blockade. 27 Reduction in proteinuria was reported with calcitriol/VDRA with a weighted mean difference from baseline of 16% (95%CI, 13-18%)) compared with an increase with control (6% (95%CI, 0-12%)). This analysis also suggested a dose-dependent effect; and the findings were consistent irrespective of study size, duration of follow-up or cause of CKD.
Progression of renal impairment
Although calcitriol/VDRA have not been shown to date to reduce the rate of deterioration of kidney function in CKD, reduction of proteinuria with calcitriol/VDRA may potentially be beneficial to slow down progression of CKD. In the REIN study, treatment with angiotensin-converting enzyme inhibitors reduced proteinuria by 15%, which was associated with a reduced risk of reaching end-stage kidney disease. 28 Although the potential mechanism of action for calcitriol/VDRA to reduce proteinuria is unclear, experimental studies suggest that renoprotection by reducing proteinuria could be caused by suppression of renin transcription, reduction in podocyte injury, anti-proliferative effects or anti-fibrotic effects, or a combination. In a recent post hoc propensity score-matched analysis derived from a prospective cohort study of 240 patients with CKD stages 4-5, the use of calcitriol/VDRA was independently associated with preservation of renal function. 29 However, definitive trials demonstrating that calcitriol/VDRA slow progression to end-stage kidney disease are lacking.
Vitamin D supplementation
'Nutritional' vitamin D supplementation (vitamins D2 and D3) can also effectively suppress PTH, although this therapy appears to become less effective in advanced CKD. 30, 31 Several studies have demonstrated that correction of vitamin D deficiency (as defined by low serum 25-hydroxyvitamin D levels) in CKD does not adequately manage SHPT, and most patients require treatment with calcitriol/VDRA. [31] [32] [33] One recent study compared nutritional vitamin D, cholecalciferol 4000 units/day for 1 month then 2000 units/day, with doxercalciferol (1 μg/day) over 3 months in CKD stages 3 and 4; and reported greater reduction in PTH with doxercalciferol (27% vs 10%, although not statistically significant). 30 There was a mild increase in serum calcium and urinary calcium excretion with doxercalciferol in this study but within the normal ranges, and otherwise, no significant differences were observed between the treatments. More recent studies have reported the effectiveness of using extended-release calcifediol, a novel vitamin D prohormone repletion therapy, to correct low serum 25-hydroxyvitamin D and improve SHPT. One RCT of 429 patients with CKD stages 3-4 showed at least a 10% reduction of intact PTH levels in 72% of participants, with no significant impact on calcium, phosphate or FGF23 levels. 34 Calcifediol may be a safe and effective treatment for SHPT in pre-dialysis CKD patients without increased risk of hypercalcaemia or other mineral disturbances; however, no trials assessing patient-centred clinical outcomes or comparison studies of calcifediol with calcitriol/VDRA have been performed to date.
Potential harms of calcitriol/vitamin D receptor activators in chronic kidney disease
The hypercalcaemic risk with calcitriol/VDRA is one of the predominant concerns with this therapy in CKD, and this risk was greater in the treatment arm of the recent placebo-controlled trials, the PRIMO and OPERA studies, compared with previous studies. This raises safety concerns when the clinical benefit remains ambiguous. Limitations of these systematic reviews include the small number of studies, small sample sizes, heterogeneity of populations and short-term follow-up. Most studies also had inadequate power and insufficient follow up to ascertain outcomes properly. If initiated for severe and progressive SHPT, calcitriol/VDRA should be started with low doses, independent of the initial PTH concentration, and then titrated based on the PTH response, to ensure hypercalcaemia is avoided.
Whether VDRA are more effective and have less risk of hypercalcaemia than calcitriol was assessed in one recent RCT, which compared 24 weeks treatment with either calcitriol (0.25 μg/day) or paricalcitol (1 μg/day), in 110 patients with CKD and PTH >120 pg/mL. 35 Adjustments of vitamin D therapy were made to achieve 40-60% suppression of PTH, with the primary endpoint being hypercalcaemia >10.5 mg/dL. ; 95%CI À0.24-0.03), but the risk of hypercalcaemia was higher in patients given calcitriol/VDRA compared with those given placebo or no medication (RR 4.78 (95%CI 2.20-10.37)), with greater RR for the VDRA. Of note, however, most of the trials were short term, generally lasting no more than 2 years.
Conclusion and suggested future research
Secondary hyperparathyroidism is an inevitable consequence of advanced CKD, and the suppression of PTH levels with calcitriol/VDRA therapy has been a cornerstone of nephrology practice. The effectiveness of calcitriol/VDRA in lowering PTH has been well established in numerous studies, and a mortality benefit of lower PTH levels has been demonstrated in many (but not all) large observational studies. However, there is still no evidence for patient-level outcomes from RCT with the use of calcitriol/VDRA in CKD; the optimal level of PTH in CKD stages 3-5 is not known; and at present, their routine use in stages 3-5 CKD cannot be recommended. Instead, there are concerns about the effects of higher doses of calcitriol/VDRA on mortality outcomes in certain CKD cohorts, with their potential to promote hypercalcaemia and, potentially, vascular calcification. Consequently, the current guidelines remain intentionally vague and are difficult to implement in clinical practice. Many aspects pertaining to the use of calcitriol/VDRA require further evaluation in clinical trials. These include their use in CKD 3-5, appropriate timing and doses, and use of calcitriol/VDRA in combination with other therapies such as phosphate binders and nutritional vitamin D. The effect of calcitriol/VDRA on the progression of SHPT and on parathyroidectomy rates also needs further investigation; and their effects on bone, fracture and musculoskeletal outcomes remain unclear. Despite the negative results of recent RCT, there is considerable interest in the use of calcitriol/VDRA for extrarenal indications such as improving cardiac outcomes and proteinuria. Future clinical trials need to evaluate clinically significant outcomes, in particular mortality and cardiovascular morbidity, as these will in turn inform revised versions of clinical guidelines pertaining to calcitriol/VDRA use. The withdrawal of reimbursement of cinacalcet therapy in Australia will afford an opportunity to re-evaluate the future use of calcitriol/VDRA in CKD, as well as refining the timing of therapy, their use in combination with other therapies, and their effects on biomarkers (other than PTH) in CKD-MBD.
